In Korea, Choi et al. observed in patients diagnosed with vivax malaria a total of 16 CYP2D6 alleles: the most common genotype was *10B/*10B, phenotypes PM+IM were more common in the recurrence group with an OR of 2.33 (95% CI, 1.14–4.77, p = 0.02), and when the association between recurrence and the activity scores was analyzed, patients with higher activity scores were significantly less likely to have a recurrence (p = 0.028), which suggests that CYP2D6 polymorphism may affect primaquine efficacy and thus Plasmodium vivax recurrence in this country [40]. This evidence concerns the gene CYP2D6 and Plasmodium vivax malaria.